Charles Truillet

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3248935/publications.pdf

Version: 2024-02-01

45 papers	1,733 citations	279701 23 h-index	289141 40 g-index
46 all docs	46 docs citations	46 times ranked	3502 citing authors

#	Article	IF	Citations
1	Pharmacokinetic Imaging Using 99mTc-Mebrofenin to Untangle the Pattern of Hepatocyte Transporter Disruptions Induced by Endotoxemia in Rats. Pharmaceuticals, 2022, 15, 392.	1.7	2
2	Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of ⁸⁹Zr-Labeled Anti-PD-L1 Antibody Formats. Journal of Nuclear Medicine, 2022, 63, 1259-1265.	2.8	11
3	Complete inhibition of ABCB1 and ABCG2 at the bloodâ€“brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [¹¹C]erlotinib. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1634-1646.	2.4	17
4	PET imaging of immune checkpoint proteins in oncology. , 2021, 222, 107786.		20
5	The Synthesis and Structural Requirements for Measuring Glucocorticoid Receptor Expression In Vivo with (Â±)-¹¹C-YJH08 PET. Journal of Nuclear Medicine, 2021, 62, 723-731.	2.8	2
6	Imaging-Based Characterization of a Slco2b1(-/-) Mouse Model Using [11C]Erlotinib and [99mTc]Mebrofenin as Probe Substrates. Pharmaceutics, 2021, 13, 918.	2.0	2
7	Quantitative Tissue Pharmacokinetics and EPR Effect of AGuIX Nanoparticles: A Multimodal Imaging Study in an Orthotopic Glioblastoma Rat Model and Healthy Macaque. Advanced Healthcare Materials, 2021, 10, e2100656.	3.9	7
8	Impact of blood-brain barrier permeabilization induced by ultrasound associated to microbubbles on the brain delivery and kinetics of cetuximab: An immunoPET study using 89Zr-cetuximab. Journal of Controlled Release, 2020, 328, 304-312.	4.8	38
9	A snake toxin as a theranostic agent for the type 2 vasopressin receptor. Theranostics, 2020, 10, 11580-11594.	4.6	5
10	An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers. Molecular Imaging and Biology, 2020, 22, 1553-1561.	1.3	11
11	Validation of Pharmacological Protocols for Targeted Inhibition of Canalicular MRP2 Activity in Hepatocytes Using [99mTc]mebrofenin Imaging in Rats. Pharmaceutics, 2020, 12, 486.	2.0	7
12	Longitudinal mouse-PET imaging: a reliable method for estimating binding parameters without a reference region or blood sampling. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2589-2601.	3.3	7
13	A Novel Radioligand Reveals Tissue Specific Pharmacological Modulation of Glucocorticoid Receptor Expression with Positron Emission Tomography. ACS Chemical Biology, 2020, 15, 1381-1391.	1.6	4
14	Profiling the Surfaceome Identifies Therapeutic Targets for Cells with Hyperactive mTORC1 Signaling. Molecular and Cellular Proteomics, 2020, 19, 294-307.	2.5	8
15	AGuIX^{Â®} from bench to bedsideâ€"Transfer of an ultrasmall theranostic gadolinium-based nanoparticle to clinical medicine. British Journal of Radiology, 2019, 92, 20180365.	1.0	86
16	New fluorine-18 pretargeting PET imaging by bioorthogonal chlorosydnoneâ€“cycloalkyne click reaction. Chemical Communications, 2019, 55, 10400-10403.	2.2	22
17	TSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma. Neuro-Oncology, 2019, 21, 755-764.	0.6	26
18	Longitudinal positron emission tomography imaging of glial cell activation in a mouse model of mesial temporal lobe epilepsy: Toward identification of optimal treatment windows. Epilepsia, 2018, 59, 1234-1244.	2.6	36

#	Article	IF	Citations
19	Development of a stress response therapy targeting aggressive prostate cancer. Science Translational Medicine, 2018, 10, .	5.8	124
20	Imaging PD-L1 Expression with ImmunoPET. Bioconjugate Chemistry, 2018, 29, 96-103.	1.8	109
21	A Preclinical Assessment of ⁸⁹Zr-atezolizumab Identifies a Requirement for Carrier Added Formulations Not Observed with ⁸⁹Zr-C4. Bioconjugate Chemistry, 2018, 29, 3476-3482.	1.8	37
22	Targeting RAS-driven human cancer cells with antibodies to upregulated and essential cell-surface proteins. ELife, 2018, 7, .	2.8	72
23	Measuring glucocorticoid receptor expressionin vivowith PET. Oncotarget, 2018, 9, 20399-20408.	0.8	8
24	⁶⁸Ga-radiolabeled AGuIX nanoparticles as dual-modality imaging agents for PET/MRI-guided radiation therapy. Nanomedicine, 2017, 12, 1561-1574.	1.7	34
25	Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Molecular Cancer Research, 2017, 15, 1221-1229.	1.5	27
26	Noninvasive Measurement of mTORC1 Signaling with 89Zr-Transferrin. Clinical Cancer Research, 2017, 23, 3045-3052.	3.2	31
27	Development of 5N-Bicalutamide, a High-Affinity Reversible Covalent Antiandrogen. ACS Chemical Biology, 2017, 12, 2934-2939.	1.6	11
28	Metabolic reprogramming ensures cancer cell survival despite oncogenic signaling blockade. Genes and Development, 2017, 31, 2067-2084.	2.7	57
29	⁶⁸Ga-PSMA-11 PET Imaging of Response to Androgen Receptor Inhibition: First Human Experience. Journal of Nuclear Medicine, 2017, 58, 81-84.	2.8	166
30	Site-Specific Radiofluorination of Biomolecules with 8-[¹⁸F]-Fluorooctanoic Acid Catalyzed by Lipoic Acid Ligase. ACS Chemical Biology, 2016, 11, 1587-1594.	1.6	18
31	A reactivity-based [¹⁸F]FDG probe for in vivo formaldehyde imaging using positron emission tomography. Chemical Science, 2016, 7, 5503-5507.	3.7	27
32	Synthesis and Characterization of ⁸⁹Zr-Labeled Ultrasmall Nanoparticles. Molecular Pharmaceutics, 2016, 13, 2596-2601.	2.3	24
33	Applying ⁸⁹Zr-Transferrin To Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins. Molecular Pharmaceutics, 2016, 13, 683-688.	2.3	12
34	Caged [¹⁸F]FDG Glycosylamines for Imaging Acidic Tumor Microenvironments Using Positron Emission Tomography. Bioconjugate Chemistry, 2016, 27, 170-178.	1.8	38
35	Ultrasmall particles for Gdâ€MRI and ⁶⁸Gaâ€PET dual imaging. Contrast Media and Molecular Imaging, 2015, 10, 309-319.	0.4	30
36	Long-Term in Vivo Clearance of Gadolinium-Based AGuIX Nanoparticles and Their Biocompatibility after Systemic Injection. ACS Nano, 2015, 9, 2477-2488.	7.3	132

#	Article	IF	Citations
37	Innovative multimodal DOTA/NODA nanoparticles for MRI and PET imaging for tumor detection. EJNMMI Physics, 2014, 1, A80.	1.3	1
38	Advantages of gadolinium based ultrasmall nanoparticles vs molecular gadolinium chelates for radiotherapy guided by MRI for glioma treatment. Cancer Nanotechnology, 2014, 5, 4.	1.9	93
39	Functionalization of Small Rigid Platforms with Cyclic RGD Peptides for Targeting Tumors Overexpressing Î±_vÎ²₃-Integrins. Bioconjugate Chemistry, 2013, 24, 1584-1597.	1.8	49
40	X-ray-Induced Singlet Oxygen Activation with Nanoscintillator-Coupled Porphyrins. Journal of Physical Chemistry C, 2013, 117, 21583-21589.	1.5	117
41	Coupling of HPLC with Electrospray Ionization Mass Spectrometry for Studying the Aging of Ultrasmall Multifunctional Gadolinium-Based Silica Nanoparticles. Analytical Chemistry, 2013, 85, 10440-10447.	3.2	28
42	Bifunctional polypyridyl-Ru(ii) complex grafted onto gadolinium-based nanoparticles for MR-imaging and photodynamic therapy. Dalton Transactions, 2013, 42, 12410.	1.6	32
43	In vivo evidence of the targeting of cartilaginous tissue by pyridinium functionalized nanoparticles. Chemical Communications, 2013, 49, 3046.	2.2	7
44	Development of gadolinium based nanoparticles having an affinity towards melanin. Nanoscale, 2013, 5, 1603.	2.8	23
45	A Topâ€Down Synthesis Route to Ultrasmall Multifunctional Gdâ€Based Silica Nanoparticles for Theranostic Applications. Chemistry - A European Journal, 2013, 19, 6122-6136.	1.7	115